Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 236

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Giacchetti, Sylvie, Bjarnason, Georg, Garufi, Carlo, Genet, Dominique, Iacobelli, Stefano, Tampellini, Marco, Smaaland, Rune, Focan, Christian, Coudert, Bruno, Humblet, Yves, Canon, Jean Luc, Adenis, Antoine, Re, Giovanni Lo, Carvalho, Carlos, Schueller, Johannes, Anciaux, Nicole, Lentz, Marie-Ange, Baron, Benoît, Gorlia, Thierry, Lévi, Francis·2006·Journal of Clinical Oncology

Abstract

Purpose: In two previous randomized trials, the adjustment of chemotherapy delivery to circadian rhythms improved tolerability and anticancer activity compared with constant-rate infusion during 5 days in patients with metastatic colorectal cancer. Patients and Methods: For this multicenter randomized trial, it was hypothesized that a chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4) would improve survival by 10% compared with conventional 2-day delivery of the same drugs (FOLFOX2). Patients were treated every 2 weeks with intrapatient dose escalation. Results: Baseline characteristics were similar in both arms for the 564 patients (36 institutions, 10 countries). Median survival was 19.6 months (95% confidence limit [CL] = 18.2, 21.2) with chronoFLO4 and 18.7 months with FOLFOX2 (95% CL = 17.7, 21.0; P = .55). The main dose-limiting toxicities were diarrhea for chronoFLO4 and neutropenia for FOLFOX2. The analysis of survival predictors showed that sex was the single most important factor (P = .001). In women, the risk of an earlier death with chronoFLO4 was increased by 38% compared with FOLFOX2, with median survival times of 16.3 and 19.1 months (P = .03), respectively. In men, the risk of death was decreased by 25% with chronoFLO4 compared with FOLFOX2, with median survival times of 21.4 and 18.3 months (P = .02), respectively. Conclusion: Both regimens achieved similar median survival times more than 18 months with an acceptable toxicity. The chronomodulated schedule produced a survival advantage over FOLFOX in men. The strong sex dependency of optimal scheduling of fluorouracil, leucovorin, and oxaliplatin calls for translational investigations of determinants related to the patient's molecular clock.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.06.1440

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 236

Metadata

Authors
Giacchetti, S., Bjarnason, G., Garufi, C., Genet, D., Iacobelli, S., Tampellini, M., Smaaland, R., Focan, C., Coudert, B., Humblet, Y., Canon, J. L., Adenis, A., Re, G. L., Carvalho, C., Schueller, J., Anciaux, N., Lentz, M.-A., Baron, B., Gorlia, T., & Lévi, F.
Venue
Journal of Clinical Oncology
Published
2006-08-01
Volume
24
Issue
22
Pages
3562-3569
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2108585052
Cited by
236
References
4
FWCI
6.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. https://app.cochat.ai/papers/10.1200/jco.2006.06.1440
The paper
Giacchetti, S., Bjarnason, G., Garufi, C., Genet, D., Iacobelli, S., Tampellini, M., Smaaland, R., Focan, C., Coudert, B., Humblet, Y., Canon, J. L., Adenis, A., Re, G. L., Carvalho, C., Schueller, J., Anciaux, N., Lentz, M.-A., Baron, B., Gorlia, T., & Lévi, F. (2006). Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.06.1440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.